Company Description: Keliomics is an emerging biotechnology company whose breakthrough platform for organ-scale biology preserves the full composition, structure, and function of primary human tissues. Its initial products are ex vivo fat and ex vivo tumors (EVTs) that leapfrog current technologies by maintaining human adipose organs alive ex vivo and growing tumors in them: for example, "breast cancer in human breast tissue". The resulting ex vivo. models have key clinical characteristics including obesity status, menopausal status, T1-T4 tumor stage, adjuvant vs. neoadjuvant states, and patient-specific responses to treatment. This groundbreaking technology generates human data before human testing, thereby helping biopharmaceutical companies achieve preclinical certainty when selecting efficacious assets to advance into clinic.